Interesting reading this post again as now we see Dr Kathleen Mahoney from Dana Farber....tied into how Dana Farber / Dr Gordon Freeman on recent PS Targeting patents....
I also liked this one
1:35 KEYNOTE PRESENTATION: POLITICS AND REALITIES OF IO COMBINATION TRIAL DESIGN Llew Keltner, M.D., Ph.D., CEO, EPISTAT An acute concern of both biotechs and KOLs in IO is getting access to anti-PD-1/PD-L1 from pharma for combination trials. The current state of combination IO trials will be reviewed. The different policies of pharma companies with clinical-stage/marketed anti-PD-1/anti- PD-L1 about access to their compounds for combination trials will be compared. Trial designs and indications that might have decent luck in getting the cooperation of these companies will be suggested.
_________
Combine that with Llew Keltners video below and ties into Heat / Pelican ...where ex analyst Rahul becomes CEO ...and I wonder if Peregrine has something to tell us this week??
Market Data 
Markets 
AI
